The American Society of Clinical Oncology (ASCO) [16], European Group on Tumor Markers (EGTM) [17], and the National Comprehensive Cancer Network (NCCN) [18] recommend the determination of ER, PR, and HER2 status for prognosis and treatment planning in all breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.